Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Descriptive Efficacy of BRII-296 in Adults With Severe Postpartum Depression (PPD)

NCT06057012 is registered in ClinicalTrials.gov with Brii Biosciences Limited as lead sponsor.

NCT NCT06057012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06057012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Descriptive Efficacy of BRII-296 in Adults With Severe Postpartum Depression (PPD)
Lead sponsor
Brii Biosciences Limited
Phase
Phase 2
Overall status
Completed
Start date
September 29, 2023
Completion date
March 13, 2024
Enrollment
11 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

severe postpartum depression